Edoxaban Dose Adjustment and Age-Associated Outcomes in Patients With Atrial Fibrillation Post-Transcatheter Aortic Valve Replacement.

ABSTRACT:

Background

In ENVISAGE-TAVI AF (EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation-in Atrial Fibrillation), there were more bleeding events with edoxaban 60 mg than vitamin K antagonists (VKAs) in patients with atrial fibrillation (AF) after transcatheter aortic valve replacement (TAVR).

Objectives

This analysis evaluated the impact of edoxaban dose adjustment criteria (eDAC) by age and treatment group (edoxaban vs VKA) on clinical events in patients with AF post-TAVR.

Methods

In this ENVISAGE-TAVI AF on-treatment analysis, patients received edoxaban 60 mg once daily-adjusted to 30 mg if they met ≥1 eDAC (creatinine clearance 15 to ≤50 mL/min, body weight ≤60 kg, or concomitant u

SUBMITTER: Van Mieghem NM 

PROVIDER: S-EPMC12805168 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature